AAV-DJ Rep-Cap plasmid (serotype DJ-specific AAV RC-DJ plasmids)

GeneMedi's AAV-DJ Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the AAV-DJ capsid protein.

You can produce AAV-DJ particle in 293T cell line in high titer using GeneMedi's AAV-DJ Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of AAV-DJ vector has been validated in retina, lung, liver and kidney, with potential applications in tissue-specific gene therapy.

Target products collectionGo to AAV vector system >>



Product Description

Cat.NO Product Name Organization Type Price(In USD)
P-RC15 AAV-DJ Rep-Cap Plasmid
Academic 1115
P-RC15 AAV-DJ Rep-Cap Plasmid
Industry R&D
(excluding
CRO&CDMO&CXO)
P-RC15 AAV-DJ Rep-Cap Plasmid
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-RC15-Kan AAV-DJ Rep-Cap Plasmid(Kan resistance)
All
Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Rep-Cap Plasmids and do not provide seed stocks.
P-PK15 AAV-DJ Vector System
1. AAV-DJ Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Academic 2388
P-PK15 AAV-DJ Vector System
1. AAV-DJ Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
Industry R&D
(excluding
CRO&CDMO&CXO)
P-PK15 AAV-DJ Vector System
1. AAV-DJ Rep-Cap Plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug
CRO&CDMO&
CXO&CMC&
Manufacturing company
P-PK15-Kan AAV-DJ Vector System(Kan resistance)
1. AAV-DJ Rep-Cap Plasmid(Kan resistance), 10mg
2. AAV Helper Plasmid(Kan resistance), 10mg
3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), 10mg
All
Currently, GeneMedi only offers amplification services for the Kan-resistant AAV Vector System and do not provide seed stocks.
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.
Terms of sale:
For Seed (5ug):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party.

For plasmid production&lification (≥10mg):
The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party.

Citation

Title Publication Date
Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor) Signal Transduction and Targeted Therapy 2024/1/24
Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456 Signal Transduction and Targeted Therapy 2023/10/19
Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation Molecular Cancer 2022/4/2
Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression Molecular Cancer 2022/3/18
Inhibiting cardiac autophagy suppresses Zika virus replication Journal of Medical Virology 2023/1/10
Oncogenic AURKA-enhanced N6-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells Cell Research 2020/8/5
Neuraminidase 1 promotes renal fibrosis development in male mice Nature Communications 2023/3/27
BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism Nature Communications 2023/3/14
PSD?93 up?regulates the synaptic activity of corticotropin?releasing hormone neurons in the paraventricular nucleus in depression Acta Neuropathologica 2021/9/18
Self-assembled ultraflexible probes for long-term neural recordings and neuromodulation Nature Protocols 2023/5/29


Validation data

Picture loading failed.
Figure. Selected transduction results of AAV in vitro (in 293T cell line)

Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopy

transduction results of AAV2 (left) /AAV-DJ (middle) / AAV9 (right) in tumor
Figure. Selected transduction results of AAV2 (left) /AAV-DJ (middle) / AAV9 (right) in tumor.

Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×1012 vg/ml
Animal: Nude mouse, 2 months
Infection site: Subcutaneous transplant of bowel cancer cells
Gene delivery method: Tumor injection, 10μl/site, 4 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

transduction of AAV9-GFP in mouse muscle
Figure. Selected transduction results of AAV9-GFP in mouse muscle.

Virus and titer: AAV-DJ-GFP, AAV9-GFP, 1×1012 vg/ml
Animal: mouse, C57, 2 months
Infection site: Kidney
Gene delivery method: Multiple sites injection in kidney 10μl/site, 6 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy


Associated products and services


Products & Service Products & Service Information
AAV Packaging service Detail
Promise-ORF™ viral CDNA library Detail
Plasmid DNA Rapid Preparation Service Detail